In a report released today, Difei Yang from Mizuho Securities maintained a Hold rating on Spark Therapeutics (ONCE), with a price target of $114.50. The company’s shares closed last Monday at $98.02.
According to TipRanks.com, Yang is a 3-star analyst with an average return of 2.9% and a 37.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Audentes Therapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for Spark Therapeutics with a $114.50 average price target.
See today’s analyst top recommended stocks >>
Based on Spark Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $64.23 million. In comparison, last year the company had a net profit of $80.17 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases.
